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TRANSLATIONAL RELEVANCE 
Tumor hypoxia is recognised as a major contributing factor in the progression of prostate cancer. 
This study provides the first evidence that a novel unidirectional hypoxia-activated prodrug, 
OCT1002, effectively targets hypoxic tumor cells; our study shows this occurs both in vitro and in 
vivo.  In a xenograft mouse model of prostate cancer, OCT1002 improves the efficacy of the anti-
androgen drug bicalutamide in controlling tumor growth. We have shown that initial treatment of 
androgen-sensitive tumors with bicalutamide causes vascular collapse and increased hypoxia; 
however, after 21 days the vasculature recovers. Our evidence shows that OCT1002 causes selective 
killing of tumor cells with a more malignant genotype. This provides a mechanistic explanation for 
why patients on hormonal therapy relapse. It also shows that targeting hypoxic tumor cells with 
OCT1002 offers a means by which malignant progression can be blocked in patients on androgen-
deprivation therapy.  
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ABSTRACT  
Purpose 
To understand the role of hypoxia in prostate tumor progression, and to evaluate the ability of the 
novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the anti-tumor effect of 
bicalutamide.  
Experimental Design  
The effect of OCT1002 on prostate cancer cells (LNCaP, 22Rv1, PC3) was measured in normoxia 
and hypoxia in vitro. In vivo, tumor growth and lung metastases were measured in mice treated with 
bicalutamide, OCT1002, or a combination. Dorsal skin fold chambers were used to image tumor 
vasculature in vivo. Longitudinal gene expression changes in tumors were analysed using PCR. 
Results  
Reduction of OCT1002 to its active form (OCT1001) decreased prostate cancer cell viability. In 
LNCaP-luc spheroids, OCT1002 caused increased apoptosis and decreased clonogenicity. In vivo, 
treatment with OCT1002 alone, or with bicalutamide, showed significantly greater tumor growth 
control and reduced lung metastases compared to controls. Re-establishment of the tumor 
microvasculature following bicalutamide-induced vascular collapse is inhibited by OCT1002. 
Significantly, the up-regulation of RUNX2 and its targets caused by bicalutamide alone were blocked 
by OCT1002.  
Conclusions  
OCT1002 selectively targets hypoxic tumor cells and enhances the anti-tumor efficacy of 
bicalutamide. Furthermore, bicalutamide caused changes in gene expression which indicated 
progression to a more malignant genotype; OCT1002 blocked these effects, emphasising that more 
attention should be attached to understanding genetic changes that may occur during treatment. Early 
targeting of hypoxic cells with OCT1002 can provide a means of inhibiting prostate tumor growth and 
malignant progression. This is of importance for the design and refinement of existing androgen-
deprivation regimens in the clinic. 
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INTRODUCTION 
Hypoxia occurs in most solid tumors and it is known to have a major influence on treatment response 
to both radiotherapy (1) and chemotherapy (2). Untreated prostate tumors are no exception and they 
have been found, in several studies, to have very low median oxygen levels (2.4mmHg; 0.3% 
oxygen)(3, 4), which is >12 times lower than oxygen levels found in the normal prostate (30 mmHg; 
3.9% oxygen)(5). Studies have shown that high levels of hypoxia significantly correlate with 
increasing clinical stage and can predict biochemical failure following radiotherapy (6). Importantly, 
hypoxia has also been implicated as a causative factor in malignant progression, with many effects 
mediated through increased expression of HIF-1 (7). In addition, hypoxia has been shown to cause 
genetic instability (8), gene amplification (9), endothelial to mesenchymal transition (EMT)(10, 11) and 
the selection of cells with diminished apoptotic potential and a greater invasive potential (12-15). 
Hypoxia is therefore a significant impediment to the successful outcome of many cancer treatments. 
One approach to blocking the influence of hypoxic tumor cells is to directly target this sub-population 
with a hypoxia-activated prodrug (HAP); these prodrugs are a diverse group of chemicals that can be 
reduced in cells when oxygen levels are very low (16, 17). The majority of HAPs are reduced in 
single-electron reduction steps, a process which is reversible when oxygen levels increase and is 
associated with superoxide formation. In contrast, alkylaminoanthraquinone di N-oxides are 
irreversibly reduced by addition of two electrons on each of the two N-oxide side arms of the 
anthraquinone ring. This results in formation of metabolically stable reduction products; for this reason 
it is proposed they should be classified separately as unidirectional HAPs (uHAPs). Currently there 
are two compounds of therapeutic interest presenting these advantageous properties, namely AQ4N 
(18) and a recently described deuterated analogue OCT1002 (OncoTherics Ltd)(19). Under tumor-
relevant hypoxic conditions the two sequential 2e− reductions yield the toxic metabolites AQ4 and 
OCT1001 respectively (5). These stable reduction products have very high affinity for DNA and they 
also target topoisomerase II (20), which can effect a long-term inhibition of both DNA replication and 
cell cycle traverse (21). OCT1002 is distinguished from AQ4N by its highly selective deuterium 
substitution of the 12 hydrogen atoms contained within the two N-oxide side chains (22).  Deuteration 
can modify the rate of cleavage of covalent bonds to deuterium, creating a deuterium kinetic isotope 
effect, slowing cytochrome P450 metabolism of the deuterated versions of drug candidates (23). 
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Further, non-covalent interactions between molecules can be modified by deuteration (24), while 
differences in the polarities of deuterated versus non-deuterated isomers can potentially alter the 
complex subcellular localization and sequestration properties (25) and contribute to an enhanced 
intracellular persistence of the activated drug OCT1001 (19). 
To test the effectiveness of these uHAPs in vivo, we routinely utilise a murine LNCaP-luc xenograft 
model of prostate cancer in our laboratory (11, 26). This is an ideal system to investigate tumor 
hypoxia, since LNCaP/LNCaP-luc tumors have a low oxygen level (~6mm Hg; 0.8% oxygen) 
comparable to that observed in patients. Furthermore, we have used this model to demonstrate that 
this level falls even further to about 0.1% oxygen upon initiation of bicalutamide treatment, due to 
vascular collapse (26). Bicalutamide is a widely used drug used in androgen deprivation therapy 
(ADT) and provides for effective control of locally advanced prostate cancer prostate tumors. However 
remissions normally last only about 18-24 months before tumors recur, often as the more highly 
metastatic castrate resistant prostate cancer (CRPC)(27). Our previous results led us to hypothesise 
that the bicalutamide-induced hypoxia may select for cells with a more aggressive phenotype, a 
selection which we subsequently demonstrated was characterised by up-regulation of several pro-
survival genes and a promotion of the EMT phenotype (11). Notably, when a single dose of uHAP 
(AQ4N) was administered during the bicalutamide-induced hypoxic phase in this model, tumor growth 
was significantly delayed (26). In the current study, we have investigated if a similar growth delay 
occurs in the same xenograft model when OCT1002 is used alone and in combination with 
bicalutamide. We also profile genetic changes in response to both bicalutamide and OCT1002 
treatment to determine if bicalutamide-induced alterations in genes associated with metastatic 
progression were blocked by the use of OCT1002. 
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MATERIALS AND METHODS  
Cell Culture 
All cell-lines were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). Cells 
were frozen at low passage number and used within 3-6 passages after thawing. Cells were 
authenticated by in-house genotyping service and routinely tested as mycoplasma-free (InvivoGen, 
Toulouse, France). A luciferase-expressing variant of the parental LNCaP cells was developed and 
confirmed to have similar characteristics to the parental cells (26). These LNCaP-luc cells were 
cultured in RPMI 1640 culture medium (Life Technologies, Paisley, UK) supplemented with 10% 
foetal bovine serum (FBS), D-glucose (10mM; Sigma, Poole, UK) and HEPES (10mM; Sigma). PC3 
and 22Rv1 were cultured in RPMI-1640 supplemented with 10% FBS. For OCT1002 treatment, 5,000 
cells were seeded in a 96 well plate and allowed to adhere overnight.  Cells were treated with 
OCT1002 (10-12 to 10-3M in vehicle) at 37°C.  After 72 hours, a cell viability XTT assay (Roche, 
Sussex, UK) was carried out. For treatment in hypoxic conditions, 5,000 cells were seeded in a 96 
well plate and allowed to adhere overnight. After dosing with OCT1002 (1µM), cells were placed in 
normoxia (20% oxygen) or hypoxia (0.1% oxygen) at 37°C in a hypoxia work station (Ruskinn 
Technology, UK) for up to 48 hours: cell viability was measured using a XTT assay. 
Spheroid 3D cell culture 
5,000 LNCaP-luc cells were seeded in non-adherent 24 well plates and spheroids allowed to form 
upon continued incubation.  On Day 7, spheroids were treated with vehicle (0.1% DMSO), 
bicalutamide (13.8 µM), OCT1002 (1 µM) or bicalutamide + OCT1002. Spheroid growth was 
measured at Day 4, 6, 8, 10, 11 and 12.  Images were taken at 100X magnification. For colony 
forming assays, spheroids were collected by centrifugation on Day 10, re-suspended as a single cell 
suspension and seeded on adherent 6 well plates. After 7 days, colonies were fixed and stained with 
crystal violet (2%). Quantification was performed by addition of 0.1% SDS to the wells and 
absorbance was measured at 595nm. Spheroids, treated on Day 4, were disaggregated and stained 
72 hours later with an Annexin/PI apoptosis kit (Life Technologies) and analysed by flow cytometry on 
a Gallios™ Flow Cytometer (Beckman-Coulter, High Wycombe, UK). 
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Quantitative Real-Time PCR  
RNA was extracted from spheroids using Trizol® (Life Technologies) and cDNA prepared using 
RevertAid reagents (Fermentas, Cambridge, UK).  Quantitative Real-Time PCR (qPCR) was carried 
out using SYBR green (Fermentas) and gene specific primers (Supplementary Table S1) on a LC480 
Lightcycler (Roche).After normalization to the reference gene(s), relative expression levels of each 
target gene were calculated using the comparative CT (ΔΔCT) method.  qPCR for miR-210 was 
performed using the miRCURY LNATM microRNA PCR system (Exiqon, Vedbaek, Denmark) using 
20ng template RNA. PCR was performed on the LC480 Lightcycler, normalization was against 
U6snRNA and relative expression levels calculated using the comparative CT (ΔΔCT) method. All 
PCR graphs represent the combined results from ≥3 independent biological replicates, unless 
otherwise indicated.   
 
Western Blotting  
Protein was extracted from spheroids using urea buffer.  Primary antibodies used were obtained from 
Cell Signaling Technology unless otherwise stated and comprised: PARP/Cleaved PARP (#9542, 
1:1000), Bax (#2772S, 1:500), Bcl-2 (#2876S,1:500), β-actin (#4967,1:1000) and GAPDH (Millipore, 
ABS16,1:1000).  Membranes were blocked in 5% BSA diluted in 1x TBS-T (0.05%) followed by 
incubation in the appropriate secondary antibody (goat anti-rabbit IgG-HRP (1:10000) or goat anti-
mouse IgG-HRP (1:10000)). Secondary antibodies were purchased from Santa Cruz Biotechnology 
(Heidelberg, Germany). 
 
In vivo methods 
Animal maintenance. In vivo experiments were conducted in accordance with the Animal (Scientific 
Procedures) Act 1986 and the UKCCCR guidelines for the welfare of animals in experimental 
neoplasia (28).  8-10 week old male BALB/c immune-compromised (SCID) mice weighing 25-30g 
(Envigo, Cambridgeshire, UK) were housed under standard laboratory conditions in a temperature 
controlled (22ºC; 50-55% humidity) pathogen free environment with a 12 hour light-dark cycle. Food 
and water was supplied ad libitum. All surgical procedures were performed under aseptic conditions 
and the body temperature of animals was kept constant using heated pads. 
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Xenograft establishment and tumor growth delay. LNCaP-luc or 22Rv1 xenografts were established 
on the dorsum of SCID mice by subcutaneous injection of 2 x 106 cells suspended in 100µl of matrigel 
with a 21g needle (Becton Dickinson, Oxford, UK). Once the tumor became palpable dimensions 
were measured using Vernier calipers.  
Drug administration. Bicalutamide was prepared in vehicle (0.1% DMSO in corn oil)(Sigma) and 
administered orally (p.o.) via gavage as 2mg/kg daily. OCT1002 (OncoTherics, Shepshed, UK) was 
prepared in sterile phosphate buffered saline (PBS) and administered as a single intraperitoneal (i.p.) 
injection (50mg/kg). When tumor volume reached between 100–150mm3, mice were randomly 
assigned to treatment groups and dosing initiated. Animals were sacrificed at day 28 or when tumor 
reached the maximum size permitted. 
Assessment of metastasis. Upon Day 28 animals were injected i.p. with D-Luciferin (150 mg/kg in 
PBS) 5 min prior to imaging.  Animals were sacrificed, lungs were removed to detect bioluminescence 
using the IVIS imaging system (Xenogen, Santa Clara, CA).  Within a region of interest the total light 
flux (photons/second) was measured. 
Dorsal skin fold model 
Dorsal skin fold (DSF) preparation. A bespoke transparent DSF ‘window chamber’ (APJ Trading Co. 
Ltd, USA) was attached to the dorsum of mice as previously described (26, 29). This consisted of a 
titanium frame with a viewing port into which a tumor fragment was placed. The DSF preparation was 
then hydrated with sterile saline and closed with a glass coverslip secured by a spring c-clip. 
Imaging of treatment-induced changes in the tumor vasculature. The tumor fragment was left in place 
for one week to allow vascularisation. Bicalutamide treatment was then initiated (day 0). Five minutes 
prior to imaging (days 0. 7, 14 and 21) mice were given 50µl 150 kDa fluorescein isothiocyanate-
labeled (FITC) dextran (50mg/ml in saline)(Sigma) into the tail vein. Mice were secured in a bespoke 
restraint and placed laterally onto a modified microscope stage. Tumor microvessels were imaged 
using a HC PL APO lens (10X magnification) fitted to a TCS SP5 confocal microscope (Leica 
Microsystems, Germany).  Three random regions of interest (ROIs) were identified at various 
locations within each tumor and consecutive images were taken. At each ROI image stacks were 
created through the z-plane of the tumor tissue with a final maximum projection created using the 
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Leica application suite advanced fluorescence (LAS AF®) software. Images were analysed offline 
using ImageJ software (National Institute of Mental Health, Maryland, USA) and stereological analysis 
performed using a Merz grid (30). Visualization of OCT1002 was performed 4 h after drug 
administration with a helium neon laser (excitation at 633nm; emission 650nm–800 nm). Images were 
subsequently merged with FITC-dextran labelled tumor vasculature. 
 
PCR custom array gene expression analysis 
5µg RNA per tumor sample was reverse transcribed using RevertAidTM (Fermentas) and cDNA from 3 
tumors per treatment on specific days (0, 7, 14, 21 and 28) were pooled.  Changes in expression 
profile were analysed on RealTime Ready custom 96 well panels (Roche)(Supplementary Figure S1). 
PCR was performed on the LC480 lightcycler and results were normalised to reference genes (HPRT, 
beta actin and 18s ribosomal RNA). Fold changes in gene expression of vehicle and bicalutamide 
treated xenografts were compared to pre-treatment (Day 0) expression levels; genes considered up-
regulated (≥2) or down-regulated (≤0.5) and those which satisfied a p value <0.05 (student t-test) 
were deemed statistically significant.  
Immunohistochemistry 
Tumors at the experimental endpoint were excised, fixed in PFA and wax-embedded. 5μM sections 
were stained with RUNX2 (27-K, 1:50), ki-67 (SP6, 1:100) and IgG antibodies (all Santa Cruz 
Biotechnology) using Superpicture 3rd Gen IHC kit (Life Technologies). Five fields per sections were 
viewed, scored and averaged.  Immunohistochemistry staining was scored using a two approach 
method for extent and intensity (31).   Extent of staining was defined as the percentage of cells with 
nuclear immunoreactivity and was scored 0-5: negative (0); ≤10% (1); 11%–25% (2); 26%–50% (3); 
51%–75% (4) and ≥76% (5).  Intensity of staining was scored 0-5: negative (0)-very strong (5). Scores 
were averaged with 3 mice per group.  
Statistical analysis 
Data from qPCR analyses and tumor growth delay studies were analysed using a two-tailed student’s 
t-test. All remaining datasets were analysed using a two-way ANOVA with Bonferroni post-test 
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analysis. All statistical analysis was carried out using the Prism 5.0 software (GraphPad). Differences 
between points were deemed statistically significant with a p<0.05 (95% confidence interval). 
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RESULTS 
Novel uHAP OCT1002 is reduced to active form OCT1001 in hypoxic conditions 
OCT1002 is electrically neutral in aqueous solution but in hypoxic tumor cells it can be reduced to the 
DNA-affinic cytotoxin OCT1001 (Figure 1A). Imaging 4 hours after OCT1002 administration on Day 7 
showed extensive distribution of drug far-red fluorescence (19) in the tumor, particularly in the more 
hypoxic centre (Figure 1B). When the tumors were imaged 7 days later the bound drug is still clearly 
visible, particularly away from blood vessels, confirming the longevity of OCT1001 in hypoxic cells. No 
autofluorescence was seen in untreated tumor fragments (Figure 1B). 
 
Activated OCT1002 targets hypoxic cells in vitro  
Treatment of 3 prostate cancer cell-lines (LNCaP-luc, 22Rv1, PC3) at a range of OCT1002 
concentrations (10-12 to 10-3M) revealed no significant toxicity at concentrations of <1μM (Figure 1C). 
When LNCaP-luc cells were grown in hypoxic conditions (0.1%) for 48 hours, there was an expected 
decrease in cell viability (Figure 1D) compared to cells grown in normoxic conditions (20%). However, 
treatment of these hypoxic cells with 1μM OCT1002 resulted in a further significant decrease in the 
viability of the cells (Figure 1D, grey bars). In contrast, OCT1002 treatment of cells grown in normoxic 
conditions had no effect (Figure 1D, white bars), indicating that the drug only targets cells in hypoxic 
conditions. Similar results were obtained for both 22Rv1 and PC3 cells (Supplementary Figure S2). 
We also utilised a 3D spheroid model of prostate cancer growth to illustrate the effect of OCT1002 on 
hypoxic LNCaP-luc cells. The increasing presence of hypoxia in growing spheroids was confirmed by 
the increasing levels of the hypoxic markers IGF1 and miR-210 (Figure 2A) and HIF1α protein (Figure 
2B). Again, the prevalence and localisation of hypoxia-activated OCT1001 in the spheroids could be 
detected in the far-red spectral window (Figure 2B, images).  The developing hypoxia occurs 
concurrently with an increase in spheroid size over a 10 day period. Addition of bicalutamide on Day 7 
significantly attenuated their growth and an even greater decrease in spheroid growth and reduction 
in size was found when OCT1002 was added (Figure 2C). Upon disaggregation, the ability of both 
bicalutamide- and OCT1002-treated spheroids to form colonies was significantly decreased in 
comparison to untreated spheroids (Figure 2D). In spheroids treated with OCT1002 there was a 
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significant increase in the number of apoptotic cells (Figure 2E, Supplementary Figure S3A). This was 
consistent with the concomitant decrease in Bcl-2 protein levels and increase in Bax protein levels, as 
well as evidence of PARP cleavage (Supplementary Figure S3B). Taken together, we conclude that 
OCT1002 is indeed activated in hypoxic conditions in vitro, resulting in increased cell death.   
 
OCT1002 in combination with bicalutamide improves tumor growth control and reduces lung 
metastases 
The LNCaP-luc xenograft mouse model of prostate tumorigenesis was used to measure the effect of 
OCT1002 in vivo (Figure 3A and 3B). Tumor growth was measured during treatment with 2mg/kg 
bicalutamide; although it initially slowed growth by Day 28 the tumor growth delay (1.09±0.55 days) 
was not significantly different from that found in the vehicle-treated group. OCT1002 was 
administered as a single low dose (50mg/kg) on Day 7, which we had previously confirmed as the 
hypoxic nadir following bicalutamide treatment. When given with vehicle, OCT1002 caused a 
moderate delay in tumor growth (3.88±0.56 days). However, when OCT1002 was combined with 
bicalutamide there was a very significant increase in tumor growth delay (22.24±5.17 days). This 
effect was significantly different from both vehicle-only and bicalutamide-only tumors from Day 16 until 
the end of the experiment (Day 28). By Day 28, vehicle-treated mice had significant metastatic spread 
to the lungs (Figure 3C). Although bicalutamide-treated mice had a slightly reduced level of lung 
metastasis this was not significant, whereas OCT1002 in combination with bicalutamide significantly 
reduced metastatic spread by ~10 fold (Figure 3D). When a similar experiment was performed in a 
22Rv1 xenograft model, the combination of OCT1002 and bicalutamide in this model also resulted in 
greater tumor growth control (Supplementary Figure S4). 
 
Effect of bicalutamide on vascular density is abrogated by OCT1002 
As previously (26) we used a DSF preparation to evaluate the effect of drug treatments on tumor 
vasculature (Figure 4A–4D, Supplementary Figure S5). Vehicle-treated tumors showed little or no 
change in vasculature over time. Treatment with a single dose of OCT1002 (50mg/kg) on Day 7 
caused a reduction in tumor microvessels when imaged on Days 14 and 21 (Figure 4A). Treatment 
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with daily bicalutamide reduced the microvessel density (MVD) by half when measured on Day 7, with 
further loss by Day 14, yet a marked vascular recovery was evident by Day 21 (Figure 4A), consistent 
with our previous studies (11, 26). Data from window chamber experiments on 22Rv1 tumors also 
showed bicalutamide-induced hypoxia and concomitant changes in vasculature similar to that 
observed for LNCaP tumors (Supplementary Figure S6). Notably, in LNCaP xenografts, OCT1002 
administered on Day 7 blocked the re-establishment of microvessels seen after 21 days of 
bicalutamide treatment (Figure 4A). Quantification of the vascular coverage at Day 21 showed 
administration of OCT1002, alone or in combination with bicalutamide, resulted in reduced MVD and 
fewer branch points compared to vehicle or bicalutamide alone (Figure 4B and 4C). Conversely, as 
expected, vessel length was increased in the presence of OCT1002, as the microvascular network 
was not re-established unlike that observed in bicalutamide-treated mice (Figure 4D). Full 
stereological measurements from Day 0-21 are shown in Supplementary Figure S5, demonstrating 
that the re-vascularisation that occurs at Day 21 with bicalutamide treatment is blocked when 
OCT1002 is present.  
 
OCT1002 modifies bicalutamide-induced changes in gene expression 
qPCR arrays were used to compare longitudinal changes in expression of 70 genes in tumors during 
treatment. Expression changes for all genes are shown as scatter plots (Figure 5A). Genes were 
significantly different if they fell to the left of the vertical line and above or below the horizontal lines 
(student t-test). Expression of most genes changed at some time during the 28 days showing that 
treatment caused complex changes in the overall genetic profile.  Notably, at Day 21, the significant 
up-regulation of many genes induced by bicalutamide treatment is not observed when bicalutamide is 
combined with OCT1002. More detailed examination of the variations in gene expression on Day 21 
revealed that the genes highlighted by filtering analysis are involved in promoting cell survival. 
Notably, the induction of these genes at Day 21 in response to bicalutamide was ablated by addition 
of OCT1002 (Figure 5B). 
 
Expression of RUNX2 and pro-survival genes induced by bicalutamide is blocked by OCT1002  
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Significantly, one of these was RUNX2, which regulates expression of several targets involved in pro-
survival pathways and which we had previously noted as important in the hypoxic stress response 
(32, 33). Immunohistochemistry revealed that addition of OCT1002 significantly reduced the 
expression of RUNX2 protein, as well as Ki67 staining, in LNCaP-luc tumors (Figure 6A). 
Furthermore, when we examined the expression of RUNX2 and several of its downstream targets, in 
our LNCaP-luc spheroid model, we also found that OCT1002 blocked the bicalutamide-induced up-
regulation of these genes (Figure 6B).   
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DISCUSSION 
Understanding the physiological and molecular characteristics of the tumor microenvironment before, 
during and after treatment is crucial in developing and improving therapies for prostate cancer (34). In 
particular, the effect of hypoxia upon tumor progression is a key consideration, since it has been 
consistently associated with an increasingly malignant phenotype. (12-15). In our studies, we have 
used a mouse LNCaP-luc xenograft model of prostate cancer; this provided an ideal method for 
monitoring genetic and physiological changes longitudinally. It enabled us to examine how targeting 
hypoxic tumor cells with the novel uHAP, OCT1002, can improve the anti-tumor efficacy of 
bicalutamide. 
As OCT1002 is a new agent, it was first necessary to confirm that the prodrug was converted to the 
active form (OCT1001) in hypoxic tumors. We have shown that the drug penetrated throughout tumor 
fragments grown in window chambers and that it remained in the reduced form for some considerable 
time (>7 days)(Figure 1A and 1B). Since most of the prodrug will have been eliminated after 4 hours 
(half-life about 45–60 mins in mice), the fluorescent signal reflects only the highly DNA-affinic 
reduction product OCT1001 which is bound in hypoxic cells. We then showed that OCT1002 at high 
concentrations (>10-6M) showed cytotoxicity against 3 prostate cancer cell monolayers and that 
OCT1002 could target hypoxic prostate cells more effectively in hypoxia (0.1%)(Figure 1C and 1D, 
Supplementary Figure S2). This confirms additional studies we have carried out showing an oxygen-
dependent enhancement of cytotoxicity in a range of other cell lines (data not shown). We also used 
LNCaP-luc spheroids to more closely recapitulate in vivo tumor formation, since hypoxia develops as 
the spheroid grows (Figure 2A-2C). We show that this spheroid hypoxia reduces OCT1002 and 
results in significant cell death, evidenced by reduced spheroid size and increased apoptotic markers. 
Furthermore, spheroids had significantly reduced ability to form colonies after treatment with 
OCT1002 as compared to controls (Figure 2D). This suggests that specifically killing hypoxic cells 
reduces viable clonogens, which may be crucial for reducing cells with metastatic potential in vivo. 
Flow cytometry suggests that OCT1002 promotes apoptosis, whereas bicalutamide induces more 
necrosis, presumably due to the differing modes of action of these drugs (Figure 2E). However, the 
combination of these agents needed to be explored in vivo to better assess how they would impact 
upon tumor growth in a more complex microenvironment. 
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Previously we have shown that bicalutamide treatment (2-6mg/kg daily) caused immediate severe 
hypoxia in LNCaP-luc xenografts over 1-14 days due to vascular collapse which slowly recovered 
over the next 14 days (11, 26). Hence we have now examined the effect of the novel uHAP, 
OCT1002, on this effect by administration of a single low dose of OCT1002 (50mg/kg) at the hypoxic 
nadir (Day 7). In combination with daily bicalutamide there was a significant slowing of tumor growth; 
this effect was observed up to the end of the experiment (Day 28), indicating that targeting hypoxic 
cells can enhance the anti-tumor effect of bicalutamide for some considerable time. Interestingly, 
treatment with OCT1002 alone also proved to be slightly more effective in controlling tumor growth 
than bicalutamide treatment alone. Presumably this is because it is activated by the inherently 
hypoxic tumor environment (5), even without the extra hypoxia induced by bicalutamide effect on the 
vasculature. Notably, OCT1002 significantly inhibited metastatic spread to the lungs, suggesting that 
targeting hypoxic cells also targets cells with increased metastatic potential.  
In the absence of another reliable androgen-sensitive xenograft model to validate our results, we 
investigated 22Rv1 xenografts. However, these tumors are very hematogenous, grow very fast in vivo 
and respond only slightly to bicalutamide. Nonetheless, bicalutamide caused marked losses in 
microvessels and profoundly reduced oxygenation, consistent with the effect in LNCaP tumors 
(Supplementary Figure S6). When OCT1002 was combined with bicalutamide there was improved 
growth control in 22Rv1 tumors (Supplementary Figure S4), suggesting that OCT1002 activation was 
improved when administered during the period of bicalutamide-induced hypoxia. Interestingly, the 
bicalutamide-treated tumors became less hematogenous and easier to work with, perhaps due to the 
anti-vascular effects of the bicalutamide. Even so, 22Rv1 tumors are more challenging to work with in 
vivo than LNCaP tumors and provide, in our opinion, a model which is of limited value for comparison 
with androgen-sensitive slow-growing human tumors. Even moderate-sized tumors start to deteriorate 
and we would urge caution at using 22Rv1 cells as xenografts. Nevertheless, our data shows that a 
single moderate dose of OCT1002 produced significant anti-tumor effects, providing further pre-
clinical evidence of the potential of OCT1002 in the treatment of prostate cancer. 
It is also notable that OCT1002 prevents the revascularisation observed during bicalutamide 
treatment in LNCaP-luc xenograft tumors, suggesting that the cells responsible for driving the 
vascular recovery are also inhibited or killed by OCT1002 (Figure 4, Supplementary Figure S5). This 
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data is particularly pertinent since several chemotherapeutic drugs have also been shown to cause 
tumor shrinkage and vascular collapse, with a corresponding reduction in oxygen levels, even when if 
this is not directly linked to the mechanism of action of the drugs (35-37). This hypoxic stress could 
provide an environment which selects for cells with increased metastatic potential that survive to 
repopulate the tumor, implying that a combination of therapies are required to prevent progression to 
a more malignant tumor. This was also the conclusion of another recent study which suggested that 
combination of ADT with inhibitors that block hypoxia-induced chemokine production may prevent 
emergence of CPRC in a mouse metastatic prostate (TRAMP) model (38). In humans, this concept 
may explain recent results from a large clinical trial that showed using docetaxel in addition to ADT 
improved relapse-free survival in patients with high-risk localised prostate cancer (39). Docetaxel 
would have added cytotoxic effect to the growth-slowing effect of bicalutamide, increasing the total 
cell kill and therefore prolonging the time to relapse. Similarly, this may also explain why widespread 
clinical testing of drugs which directly target tumor angiogenesis have not provided the panacea that 
was expected, perhaps because they drive hypoxic selection of more malignant cells, which survive to 
resist further treatment (40). Indeed, the LNCaP xenograft model presented here would be ideal for 
studying effects of other commonly used prostate cancer drugs, such as enzalutamide and 
abiraterone, to investigate this phenomenon further and to help inform clinical practice. 
We were also interested to see how OCT1002 would impact upon gene expression patterns that we 
have previously investigated in profiling the response to bicalutamide treatment alone (11). We 
screened a set of 70 genes at each time-point in the treatment groups and filtered the data to identify 
genes which were consistently and significantly altered (Figure 5A). We focused on results from Day 
21, since we expected the hypoxic stress at this time to be reflected in the gene signatures within the 
tumors. We noted that bicalutamide treatment induced an up-regulation in a large number of genes at 
Day 21 in response to the severe hypoxia. However, this was largely absent at this time-point when 
OCT1002 was combined with bicalutamide. Further examination of the genes affected at Day 21 
(Figure 5B), showed that they reflected genes involved in promoting cell survival through various 
mechanisms such as angiogenesis, transcription, adhesion, invasion, apoptosis and cell cycle 
maintenance. Notably, the induction of almost all these genes at Day 21 in response to bicalutamide 
was ablated by addition of OCT1002 (Figure 5B). These results support our proposal above that 
some cells can survive the bicalutamide-induced hypoxia and that this is linked to up-regulation of an 
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array of pro-survival genes, which help re-establish the tumor vasculature. Ultimately, this could result 
in the hypoxia-driven selection of cells which exhibit a more aggressive, malignant phenotype. 
Worryingly, this suggests that bicalutamide use in patients may in fact increase prostate cancer tumor 
hypoxia soon after treatment, thereby selecting for cells which have increased metastatic potential. 
Our data corroborates previous studies of prostate cancer cells which have shown that hypoxia can 
indeed select for cells with a more malignant genotype/phenotype (13, 41, 42), with several reports 
detailing the up-regulation of various genes in response to hypoxic insult, including those associated 
with a pro-angiogenic phenotype (43), stem cell maintenance (44), genetic instability (8), protection 
from apoptosis (45) and malignant progression (15). With this in mind, it is significant that the up-
regulation of pro-survival genes is not observed at Day 21 when the OCT1002 is combined with 
bicalutamide. This indicates that the cells which survive the hypoxic insult, and subsequently alter 
gene expression, are targeted and killed, which is evidenced in increased tumor growth control.  
We have previously highlighted the link between hypoxic stress and RUNX2 (32, 33), so we were 
interested to see that induction of RUNX2 expression by bicalutamide treatment was effectively 
blocked by OCT1002 exposure. This is significant because RUNX2 expression is up-regulated in 
prostate (46), breast (47, 48) and colon cancer (49) and is thought to contribute to a more aggressive, 
metastatic phenotype by altering expression of many genes involved in migration, invasion, 
metastasis, apoptosis and angiogenesis (32, 46, 49). Similarly, in this study, the induction of RUNX2 
correlated with induction of several of its downstream targets (Figure 6A). However, when OCT1002 
was added to a bicalutamide treatment, the induction of RUNX2 and the associated targets was not 
observed, even though a significant hypoxic stress still existed in these tumors given that the 
vasculature had not been restored. Confirmation of this effect was found when we examined RUNX2 
expression and other genes in our spheroid model (Figure 6B).  This corroborates our previous work 
which proposes RUNX2 is a key regulator in helping cells survive the hypoxic stress. Our study 
suggests that the addition of OCT1002 targets those cells, thereby preventing RUNX2 up-regulation 
and subsequently the development of more aggressive tumor cells. Our proposed model is shown in 
Figure 6C, wherein the hypoxic-resistant cells within the heterogenous tumor cell population survive 
to repopulate the tumor, leading to relapse and CPRC development. However, addition of OCT1002 
targets these cells, preventing regrowth of the microvasculature in particular and thereby exerting 
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greater tumor growth control. Future work will further characterise the exact role of RUNX2 and other 
key molecular changes during this process. 
 
Conclusions 
In conclusion, this study shows that the novel uHAP OCT1002 effectively targets hypoxic prostate 
cancer cells and improves the ability of bicalutamide to control growth of human prostate tumours in 
mice We propose that the enhanced efficacy is due to selective killing of cells that would otherwise 
survive the severe hypoxic conditions induced by vascular collapse soon after initiation of 
bicalutamide treatment. Since the genes up-regulated during bicalutamide treatment are 
predominantly pro-survival, we hypothesise that these cells survive to establish a tumor with a more 
malignant phenotype; this may help explain why patients treated solely with ADT exhibit a relatively 
early relapse. However, our data suggests that inclusion of OCT1002 at the early stage of the ADT 
regimen to eliminate hypoxic cells could provide a method for eradication of the more malignant 
hypoxic cell population. Our data provides increased understanding of the physiological and 
molecular changes in the prostate cancer microenvironment that occur during treatment and we 
suggest that more awareness of these changes should be taken into account when deciding on ADT 
schedules for prostate cancer patients. 
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FIGURE LEGENDS 
Figure 1. OCT1002 targets prostate cancer cells in hypoxic conditions  
(A) Structure of unidirectional hypoxia-activated prodrug OCT1002 and its reduction product 
OCT1001. (B) LNCaP-luc tumors grown in a dorsal skin flap. Images show FITC-dextran labelled 
tumor vasculature (green) and activated OCT1002, i.e. OCT1001 (blue); this is visible in hypoxic 
regions 4 hours after administration on Day 7 (middle panel) and is still present 7 days later (right 
panel). Untreated tumors show no auto-fluorescence (left panel). (C) Treatment of LNCaP-luc, 22Rv1 
and PC3 prostate cancer cell-lines revealed no significant toxicity at concentrations of OCT1002 
<1μM. (D) Treatment of LNCaP-luc cells with 1μM OCT1002 significantly decreased viability of cells 
grown in hypoxia (0.1% oxygen) but not in normoxia (20% oxygen). All images and blots are 
representative of 3 independent experiments. Data shown in graphs are mean ± SE (Student t-test p-
values: *p<0.05, **p<0.01, ***p<0.001, ns; not significant) 
Figure 2. OCT1002 targets cells in LNCaP-luc spheroids 
(A) Hypoxic markers HIF1A, IGF-1 and miR-210 in LNCaP spheroids after 10 days growth. (B) 
Images reveal evidence of hypoxia in LNCaP spheroids as shown by the presence of reduced 
OCT1002 (i.e. OCT1001). Western blots show increased HiF1α protein after 10 days growth, 
compared to day 7. Cycling normoxic LNCaP-luc cells are included as control. (C) Graph and 
representative inset images show spheroid growth is reduced by OCT1002 (1µM) alone or in 
combination with bicalutamide compared to vehicle (0.02% DMSO in media) or bicalutamide (13.8µM) 
alone. (D) Crystal violet staining of colonies formed from cell disaggregates of spheroids, treated as 
(C) above. (E) Annexin V/PI apoptosis assay showing that OCT1002 induces apoptosis. Data is mean 
± SE from triplicate experiments (Student t-test p-values: *p<0.05, **p<0.01, ***p<0.001, ns; not 
significant)  
Figure 3. OCT1002 slows LNCaP-luc tumor growth in vivo  
(A) Graph shows tumor growth in LNCaP-luc xenograft SCID mouse implants following treatment with 
vehicle (0.1% DMSO in corn oil), bicalutamide (2mg/kg/day), vehicle + OCT1002 (50mg/kg 
administered on day 7), bicalutamide + OCT1002. (B) Representative images of in vivo and excised 
tumors; quantification of tumor weights (C) Representative images and (D) histogram showing extent 
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of bioluminescent metastatic LNCaP-luc cells in lungs at day 28. (Data is mean ± SE from ≥5 animals 
per group. 2way ANOVA with Bonferroni post-tests used to compare statistical significance between 
vehicle and bicalutamide treatment groups; *p<0.05, ** p<0.01, *** p<0.001 and bicalutamide and 
combination treatment groups; ^ p<0.05, ^^ p<0.01, ^^^ p<0.001) 
Figure 4. Effect of OCT1002 on vascularisation of LNCaP-luc tumor fragments 
(A) Representative images of LNCaP-Luc tumor vasculature imaged via confocal microscopy 
following i.v. injection of FITC-dextran prior to commencing treatment (day 0) and at day 7, 14 and 21 
days post-treatment with vehicle (1% DMSO), bicalutamide (2mg/kg/day), vehicle + OCT1002 
(50mg/kg administered on day 7) or bicalutamide + OCT1002. Stereological analysis was used to 
quantify changes in the vasculature of LNCaP xenografts on day 21 including (B) vessel branch 
points (C) vessel density, and (D) average vessel length. Images (10X magnification) are 
representative of ≥3 mice per treatment. Scale bar = 100µM. (Student t-test p-values: *p<0.05, 
**p<0.01, ***p<0.001, ns; not significant) 
Figure 5. Gene expression induced by bicalutamide is altered by addition of OCT1002 
(A) Comparison of gene expression in tumors excised on day 7, 14, 21 and 28 from mice treated daily 
with bicalutamide (top row) or in combination with OCT1002 (50mg/kg) on day 7 (bottom row). Data in 
scatterplots was generated using quantitative PCR arrays, which, were carried out on pooled RNA 
from tumors excised at each time-point (n≥3 per group). Gene expression changes for each treatment 
group were calculated relative to day 0 results. Horizontal lines show 2-fold change in expression and 
vertical lines display p-value of 0.05 as calculated by student t-test. (B) Comparison of gene changes 
on day 21 between vehicle, bicalutamide and bicalutamide + OCT1002 treatment groups for genes 
which were consistently and significantly altered between groups. 
Figure 6. Up-regulation of pro-survival genes induced by bicalutamide is blocked by OCT1002  
(A) Quantification of immunohistochemical staining of Ki67 and RUNX2 protein expression in LNCaP-
luc tumors (data generated from ≥3 mice per treatment). Insets show RUNX2 staining (brown) present 
in LNCaP-luc tumors at the experimental endpoint (B) Expression of RUNX2 and downstream targets 
in LNCaP-luc spheroids. Data is mean ± SE from triplicate experiments. (Student t-test p-values: 
*p<0.05, **p<0.01, ***p<0.001, ns; not significant) (C) Proposed hypothesis for beneficial effect of 
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bicalutamide and OCT1002 combination. Cells which survive the bicalutamide-induced hypoxic stress 
can re-populate the tumor and progress to CPRC. Addition of OCT1002 targets these cells, prevents 
re-establishment of tumor microvasculature, and exerts greater tumor growth control.  






